Alirocumab

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting newer medications that could be added to statin therapy or used on patients intolerant to statins.

Regeneron Pharmaceuticals announced the FDA extended its approval of alirocumab as an adjunct to diet and other LDL-lowering therapies to include patients aged 8 years and older with heterozygous familial hypercholesterolemia.

Healio and Cardiology Today have compiled the top cardiology headlines of May 2023.

A unanimous U.S. Supreme Court decision has allowed Regeneron and Sanofi to continue selling alirocumab after Amgen alleged they infringed two of its patents for PCSK9 inhibitor technology.

The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market.

PCSK9 inhibition with alirocumab, on top of high-intensity statin therapy, resulted in significant coronary plaque regression among patients with familial hypercholesterolemia and no clinical atherosclerotic CVD, researchers reported.

Treatment effect of the PCSK9 inhibitor alirocumab (Praluent, Sanofi/Regeneron) vs. sham control on LDL in patients with STEMI referred for primary PCI.

BOSTON — PCSK9 inhibition before primary PCI for STEMI, on top of standard statin therapy, significantly lowered LDL at 6 weeks compared with sham control, according to the results of the EPIC-STEMI trial presented at TCT 2022.

Effects of alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis in patients with acute MI undergoing PCI.